Your browser doesn't support javascript.
loading
Twenty plus Years of Data Demonstrating Virus Filtration as an Effective and Robust Step for Large Virus Removal.
Stanley, Brad; Holmes, Veronica; Manzari, Richard; Romanowski, Cara; Tessarz, Anja; Ruppach, Horst; Schreffler, John.
Afiliação
  • Stanley B; Biogen, Inc., Process Biochemistry, 5000 Davis Drive, Research Triangle Park, NC.
  • Holmes V; Janssen R&D LLC, Biotherapeutic Development API, 200 Great Valley Parkway, Malvern, PA.
  • Manzari R; WuXi Advanced Therapies, Viral Clearance, 4751 League Island Boulevard, Philadelphia, PA; and.
  • Romanowski C; WuXi Advanced Therapies, Viral Clearance, 4751 League Island Boulevard, Philadelphia, PA; and.
  • Tessarz A; Charles River Laboratories Germany GmbH, Biologics Testing, Gottfried-Hagen Strasse 20, 51105 Köln, Germany.
  • Ruppach H; Charles River Laboratories Germany GmbH, Biologics Testing, Gottfried-Hagen Strasse 20, 51105 Köln, Germany.
  • Schreffler J; Janssen R&D LLC, Biotherapeutic Development API, 200 Great Valley Parkway, Malvern, PA; jschreff@its.jnj.com.
PDA J Pharm Sci Technol ; 76(1): 1-8, 2022.
Article em En | MEDLINE | ID: mdl-33990425
ABSTRACT
Virus filtration has been demonstrated to be an effective and robust dedicated viral clearance step that is used in biopharmaceutical manufacturing processes. Here we present virus filtration data from a multicompany collaboration with data compiled from WuXi Advanced Therapies' and Charles River Laboratories' internal viral clearance databases spanning more than 25 years. The data were sorted by virus removal and type and then further subdivided into murine leukemia virus only, pseudorabies virus only, and reovirus type 3 only categories to allow for analyses of viral clearance results. A total of 2311 virus filtrations were analyzed, composed of 1516 murine leukemia virus, 385 pseudorabies virus, and 410 reovirus type 3 virus filtrations. These data provide clear evidence that will help supplement both internal and industry-wide initiatives focused on using prior knowledge for the creation of modular claims for small virus retentive filters and allow better allocations of resources typically spent on potentially unnecessary studies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírus / Produtos Biológicos Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírus / Produtos Biológicos Idioma: En Ano de publicação: 2022 Tipo de documento: Article